News for Mirati Therapeutics, Inc. (MRTX)

bluebird bio (NASDAQ: BLUE) (”œbluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds mana

The SERDs market is expected to grow significantly in the coming years. This is due to the increasing cancer diagnosis, high unmet need in ESR1 mutation...

The rising global incidence of breast cancer, driven by lifestyle changes and an aging population, is a key market driver. Technological advancements in...

According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness...

SAN MATEO, Calif. —

Renal cancer, also known as kidney cancer, is a disease where malignant (cancer) cells form in the tissues of the kidneys. Smoking, obesity, hypertension,...

Tango Therapeutics is a high-risk, high-reward opportunity in the field of PRMT5-inhibitor drugs targeting MTAP-deleted cancers. Read more on TNGX stock here.

The global increase in cancer cases is the main factor driving the demand for supportive care drugs. Additionally, the growing incidence of adverse effects...

Advanced kidney cancer refers to a stage of kidney cancer where the disease has spread beyond the kidney to other parts of the body, requiring more complex...

US FDA approves Bristol Myers' colorectal cancer therapy

Schrödinger has suffered setbacks over the past year, but near 52-week lows, the stock presents substantial value. Read more on SDGR stock here.

Multibillionaire Joe Lewis to face US sentencing for insider trading

Tango Therapeutics has 2 PRMT5 inhibitors in clinical development. Its shares spiked after positive data from PRMT5 inhibitor. Find out why TNGX stock is a Buy.

British billionaire Joe Lewis to plead guilty to US charges, lawyer says

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 billion

Nanomedicine is experiencing heightened demand, mainly propelled by the increasing occurrence of chronic ailments like cardiovascular, neurological,...

The demand for biopharmaceuticals is primarily driven by the increasing prevalence of chronic, infectious, and neurological diseases, coupled with the...

The dynamics of the intratumoral cancer therapies market are anticipated to change in the coming years owing to the approval of several drugs targeting...

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies...